Products & Services

CNS Services

Partner with scientific experts to evaluate central nervous system safety and efficacy across therapeutic modalities, including small molecules, ASOs, and gene therapies. Our services span established CNS-3D assay workflows, custom study designs, and custom model development to generate decision-ready data for preclinical drug development.

Human Organoid Services for CNS Safety and Efficacy

CNS Services help drug development teams translate complex CNS questions into clear, actionable preclinical insights. With a portfolio of CNS models for neurotoxicity assessment, neuroinflammation, and myelination, our CNS Services support human-relevant drug safety and efficacy studies across a range of therapeutic areas.

Services include established CNS-3D assay workflows, custom study designs, and custom model development, enabling teams to generate decision-ready CNS data without building organoid expertise in-house.

CNS Key Advantages

Human CNS Biology

Assess drug effects in human iPSC-derived cortical organoids with multicellular complexity.

Functional Neural Activity

Measure drug-induced changes in neuronal network activity.

Broad Study Applications

Access flexible CNS study options for safety, efficacy, disease modeling, and custom research needs.

Efficient Turnaround

Receive study reports in as little as 4 weeks, enabling timely decisions for preclinical program advancement.

Service

CNS Toxicity

Predict CNS toxicity risk by measuring drug-induced changes in neuronal network activity.

By measuring functional disruption of neuronal network activity, CNS-3D enables confident identification of neurotoxic liabilities across diverse modalities, outperforming animal models by 13x. CNS-3D Brain Organoids achieve 83% sensitivity and 89% specificity in predicting clinical seizure liability for small molecules, and 92% sensitivity and 92% specificity for ASOs.

Learn More

Sensitivity and specificity comparison for small molecule seizure risk prediction, demonstrating superior performance of CNS-3D versus alternative models.

Service

Gene Therapy

Prioritize gene therapy vectors using functional, human data.

CNS-3D Brain Organoids integrate assessment of transduction efficiency, toxicity, and functional impact in a single model. In AAV studies, this approach resolves serotype- and promoter-dependent differences in vector performance and detects disruption of neuronal network activity before overt viability loss.

Representative images of AAV transduction in CNS-3D Brain Organoids, demonstrating clear serotype- and promoter-dependent GFP expression.

Service

Neuroinflammation

Evaluate anti-inflammatory drug efficacy in a human neuroimmune model.

Recapitulate hallmarks of neuroinflammation—including microglial activation, pro-inflammatory cytokine release, and disruption of neuronal network activity—and evaluate anti-inflammatory therapeutics with CNS-3D Inflammatory Organoids. Integrated functional and inflammatory endpoints help quantify drug candidate efficacy and support human-relevant prioritization of therapies that suppress inflammation and preserve neural function.

Learn More

LPS stimulation increases microglial and astrocyte signal in CNS-3D Inflammatory Organoids, as shown by IBA1 and GFAP staining under control and inflammatory conditions.

Service

Alzheimer’s Disease

Assess Alzheimer’s drug efficacy in a human model of amyloid-driven pathology.

Induce Alzheimer’s-relevant phenotypes—including tau phosphorylation, apoptosis, neuronal network disruption, and gene expression changes—through exogenous amyloid beta exposure in the CNS-3D Induced Alzheimer's model. This assay enables higher-throughput evaluation of whether drug candidates reduce amyloid-driven pathology and preserve neuronal function.

Learn More

Amyloid beta oligomers induce concentration-dependent suppression of neuronal network activity, measured by calcium imaging.

Service

Myelination

Evaluate remyelinating drug efficacy by quantifying myelin loss, recovery, and repair.

CNS-3D Myelinated Organoids enable the quantification of myelin loss, natural recovery, and drug-induced remyelination in a human context that better reflects the slower, often incomplete myelin loss and repair dynamics seen in human disease. Integrated structural, functional, and molecular endpoints reveal whether drug candidates restore myelin integrity and improve neural function.

Learn More

Representative image of CNS-3D Myelinated Organoid at 12 weeks, showing neurons (NFH, magenta) and myelinating oligodendrocytes (MBP, green).

Service

Custom Services

Custom CNS studies tailored to your research objectives.

Custom Services offer tailored endpoint panels, modified study designs, and custom disease model development. For genetic disease modeling, organoid models are generated from iPSC lines provided by your team or CRISPR-engineered mutations, enabling human-relevant assessment of disease biology and therapeutic response.

How We Work Together

Schedule a Consultation

Scientific Alignment

Meet with expert scientists to define your research question, study objectives, decision criteria, and success measures.

Experimental Design

Our scientists translate your research objectives into a detailed experimental plan designed to generate decision-ready data.

Study Execution

Your study is executed by using established workflows, with regular project updates throughout the engagement.

Data Review & Reporting

Receive a detailed study report and meet with our scientists to review results, discuss key findings, and align on next steps.

Related Resources

CNS Services Resources

Explore resources for evaluating CNS safety, disease biology, and drug efficacy.

Scientific Poster

4/17/2026

CNS-3D Functional Organoids Predict Clinical Neurotoxicity Outcomes for Small Molecules and Anti-sense Oligonucleotides

Webinar

4/9/2026

Predicting Clinical Seizure Liability Before First-in-Human: New Data from the Endurance Study

Application Note

3/31/2026

CNS-3D Brain Organoids Predict Clinical Seizure Liability

Webinar

11/20/2025

Predicting Human Cognitive Outcomes with Organoid Intelligence

Application Note

6/5/2025

Modeling CDKL5 Deficiency Disorder with CNS-3D Organoids for Streamlined Target Discovery

Ready to get started?

Connect with our team to discuss your research goals and identify the 28bio organoid model best aligned to your study aims.